Scientific article
English

Update on evidence for treatment with ranolazine in stable angina

Published in

Schweizerische medizinische Wochenschrift, vol. 143, w13874

Publication date

2013

Abstract

Chronic angina represents a major burden for public health systems because of its poor prognosis and its high treatment costs. Ranolazine is an emerging drug recently approved for the treatment of this disease. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. Moreover, this particular mechanism of action also confers on ranolazine a potential antiarrhythmic effect. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.

Keywords

  • Acetanilides/therapeutic use
  • Angina, Stable/drug therapy
  • Humans
  • Piperazines/therapeutic use
  • Sodium Channel Blockers/therapeutic use
  • Treatment Outcome

UNIGE research groups

Citation (ISO format)

CARBONE, Federico, MONTECUCCO, Fabrizio, MACH, François. Update on evidence for treatment with ranolazine in stable angina. In: Schweizerische medizinische Wochenschrift, 2013, vol. 143, p. w13874. doi: 10.4414/smw.2013.13874

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0036-7672
513views
0downloads

Technical informations

Creation

14/10/2015 15:48:00

First validation

14/10/2015 15:48:00

Update

21/01/2025 16:10:56

Status update

21/01/2025 16:10:56

Last indexation

21/01/2025 16:18:33
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated